Corvus Pharmaceuticals, Inc. · NASDAQ:CRVS

Corvus Pharmaceuticals — American Society of Hematology 2025 Annual Meeting

16 slides from Corvus Pharmaceuticals's conference presentation, 2025

  1. Slide 1: Final Results of a Phase 1 Trial with Soquelitinib in R/R T Cell Lymphomas

    American Society of Hematology, 2025 Annual Meeting Final Results of a Phase 1 Trial with Soquelitinib (SQL), a Selective Interleukin-2-Inducible T Cell Kinase (ITK) Inhibitor for Treatment of Relapsed/Refractory (R/R) T Cell Lymphomas (TCL) Richard Miller, MD Richard Miller1, Ryan Wilcox2, John Ren

  2. Slide 2: ITK Involved in Many T Cell Functions

    ITK Involved in Many T Cell Functions Plays critical role in TCR signaling ITK role in TCR signaling pathway TCR/CD3 complex CD28 T cell activation ITK Migration and homing PLCg PI3K AKT Proliferation NFκB ERK NFAT mTOR Tonic TCR Signaling Somatic mutations in TCR pathway drive lymphomagenesis GATA3

  3. Slide 3: Soquelitinib Blocks Th2 and Th17 and Induces Th1 Skewing

    Soquelitinib Blocks Th2 and Th17 and Induces Th1 Skewing Modulation of T cell differentiation ITK blockade leads to increase in Th1 ITK involved in T cell differentiation and reduction in Th2, Th17 “Th1 skewing” T H1 Th1 cells play a role in cancer T H1 Th1 cells play a role in cancer T-bet T-bet ce

  4. Slide 4: Soquelitinib Selectivity

    Soquelitinib Selectivity Chemical Structure GATA3 Inhibition Kinase Binding Comparison to Ibrutinib Soquelitinib Ibrutinib Inhibition of PLCγ phosphorylation Drug Discovery 2024, 1:2 4

  5. Slide 5: Induces Th1 skewing in vitro in Normal T Cells

    Induces Th1 skewing in vitro in Normal T Cells Concentration dependent effects Th1 cells (ratio IFNγ:IL-4) dose response effect High concentrations block T cell proliferation in vitro 15 100 3 90 10 2 Viability (%) Cells (106/ml) Th1 Cells 80 70 5 1 60 0 50 0 0.001 0.01 0.1 1 10 0.00 0.01 0.1 0.3 1

  6. Slide 6: Phase I Clinical Trial Design

    Phase I Clinical Trial Design • To evaluate safety Objectives • To determine target occupancy and PK • To characterize anti-tumor activity Eligibility Dose Escalation Expansion PTCL including: 100 mg BID • PTCL-NOS • TFHL 200 mg BID 200 mg BID • NKTCL in select histologies • CTCL 400 mg BID • ALCL (

  7. Slide 7: Patient Baseline Characteristics

    Patient Baseline Characteristics Dose Escalation Dose Expansion Total Patient Characteristics (N=27) (N=48) (N=75) Age (yrs.), median (range) 62 (29, 80) 61 (21, 84) 62 (21, 84) Gender, male N (%) 15 (55.6) 28 (58.3) 43 (57.3) No. of prior therapies, median (range) 4 (2, 15) 3 (1, 18) 3 (1, 18) Best

  8. Slide 8: PK and ITK Target Occupancy

    PK and ITK Target Occupancy 200mg provides durable target occupancy Plasma Soquelitinib and ITK Occupancy in PBMCs Trough ITK Occupancy for Cycle 1 Plasma Soquelitinib and ITK Occupancy in PBMCs Following a 100 mg or 600 mg QD Dose with BID ITK Trough Dosing of Soquelitinib Occupancy for Cycle 1 Fol

  9. Slide 9: Anti-tumor Activity in Various Dosing Cohorts

    Anti-tumor Activity in Various Dosing Cohorts 9

  10. Slide 10: Anti-tumor Activity in 200 mg BID Cohort

    Anti-tumor Activity in 200 mg BID Cohort 10

  11. Slide 11: Anti-tumor Activity in 200 mg BID Cohort

    Anti-tumor Activity in 200 mg BID Cohort Role of baseline immunocompetence based on prior therapies 1-3 prior therapies 1-3 prior therapies N=24 N=24 6 CR, 3 PR >3 prior therapies Median=6 (4–18) N=12 11

  12. Slide 12: Anti-tumor Activity in Refractory PTCL, CTCL

    Anti-tumor Activity in Refractory PTCL, CTCL PTCL-NOS PTCL-NOS CTCL-MF Failed CHOP, HDACi Failed CHOP and auto-BMT Transformed large cell 12

  13. Slide 13: Soquelitinib Treatment Effects on Th1, Th2, Th17

    Soquelitinib Treatment Effects on Th1, Th2, Th17 50 CXCR3+(CD183+)Th1 cells Increase in Th1 Gene Expression % CD4+ T Cell in blood 40 CCR6+(CD196+)Th17 cells Frequency of RNA seq of paired tumor biopsies (N=6, 30 Th1 & Th17 day 0 vs 8) 20 CD4 cells in Blood 10 0 Day 1 Day 8 Day 22 Day 43 50 Tbet (TB

  14. Slide 14: PFS & OS in 200 mg Cohort with 1-3 Prior Therapies

    PFS & OS in 200 mg Cohort with 1-3 Prior Therapies Progression-free Survival Overall Survival Median PFS: 6.2 months Median OS: 28.1 months 18-month PFS: 30% 24-month OS: 67% 14

  15. Slide 15: Adverse Event Summary

    Adverse Event Summary All causality grade ≥3 adverse events 100 mg 200 mg 400 mg 600 mg Total (N =4) (N=46) (N=9) (N=16) (N=75) Preferred Term n (%) n (%) n (%) n (%) n (%) Subjects with any Grade ≥3 AE 1 (25.0) 12 (26.1) 3 (33.3) 6 (37.5) 22 (29.3) Pruritus 0 (0.0) 2 (4.3) 1 (11.1) 1 (6.3) 4 (5.3)

  16. Slide 16: Summary

    Summary • Soquelitinib is an oral selective ITK inhibitor • MOA appears based on induction of host anti-tumor response or possibly other effects on tumor microenvironment • Potential direct effect on tumor cells • Doses up to 600 mg BID well tolerated with no DLTs observed • Durable objective respon

Corvus Pharmaceuticals — American Society of Hematology 2025 Annual Meeting on 6ix